Suzhou ASTRABIO Co., Ltd.

Neuronal PPP2R5C in plasma is a potential biomarker for early diagnosis of Alzheimer’s disease 【Highlights】 •PPP2R5C is an early-declining marker across pre-sym...

Synaptic Vesicle Glycoprotein 2A Suppresses Amyloidogenesis Beyond Its Synaptic Role: A Novel Mechanism Disrupting BACE1 Binding and Altering APP Localization 【ABSTRACT】...

Plasma p-tau species are elevated in presymptomatic and symptomatic neuronal intranuclear inclusion disease 【Background】 Neuronal intranuclear inclusion disease (NIID), c...

Sorafenib promotes the E3 ubiquitin ligase FBXW7 to increase tau degradation and ameliorate tauopathies 【Abstract】 Tauopathies, including Alzheimer's disease (AD), are a series...

【Abstract】 【Background】 Current methods for the early detection of Alzheimer’s disease (AD) are constrained by high costs, invasiveness, and limited accessibility, underscoring the urgent need fo...

【Abstract】 Genetic investigations and associations with plasma biomarkers of dementia with Lewy bodies (DLB) in East Asian populations are lacking. The aim of our study is to identify candidate patho...

【Background】 Ethnic variations and detection methods may lead to differences in diagnostic biomarkers of dementia, and few comparative studies have evaluated the six plasma biomarkers of Alzheimer’s ...

【Background】 Alzheimer’s disease (AD) involves complex alterations in biological pathways, making comprehensive blood biomarkers crucial for accurate and earlier diagnosis. However, the cost-effectiv...